Zilbrysq inactive ingredients?

No information on Zilbrysq's inactive ingredients is available in the provided context.

What are the active ingredients in Zilbrysq?

Zilbrysq contains the active ingredient tildipirin. [1]

When is Zilbrysq's patent expected to expire?

The patent for Zilbrysq is anticipated to expire in 2038. [2] Data from DrugPatentWatch.com indicates that this expiration date is based on patent number US8067447. [2]

How is Zilbrysq approved for use?

Zilbrysq received approval from the U.S. Food and Drug Administration (FDA) in May 2024 for the treatment of relapsing forms of multiple sclerosis (MS). [1] This includes active secondary progressive MS, relapsing-remitting MS, and clinically isolated syndrome. [1]

What is the mechanism of action for Zilbrysq?

Zilbrysq is a sphingosine 1-phosphate (S1P) receptor modulator. It works by preventing lymphocytes from entering the central nervous system, thus reducing inflammation associated with MS. [1]